Commentary: Significance of intratumoral genetic heterogeneity in neuroblastomas

Medical and Pediatric Oncology

Volumn 38, Issue 2, 2002, Pages 112-113

  Brodeur, Garrett M ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; DISEASE CLASSIFICATION; GENE AMPLIFICATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HUMAN; NEUROBLASTOMA; NOTE; PRIORITY JOURNAL; CHROMOSOME 1; GENETIC MARKER; GENETICS; INFANT; MALE; ONCOGENE MYC; PATHOLOGY; TRISOMY;

CHROMOSOMES, HUMAN, PAIR 1; GENE AMPLIFICATION; GENES, MYC; GENETIC HETEROGENEITY; GENETIC MARKERS; HUMANS; INFANT; MALE; NEOPLASM STAGING; NEUROBLASTOMA; TRISOMY;

EID: 0036152104     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.1282     Document Type: Note

References (15)

1. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma
2. Revisions in the international criteria for neuroblastoma diagnosis, staging, and response to treatment
3. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma
4. Terminology and morphologic criteria of neuroblastic tumours: Recommendations by the International Neuroblastoma Pathology Committee
5. The international neuroblastoma pathology classification (the Shimada system)
6. Neuroblastoma
7. The International Neuroblastoma Risk Groups (INRG): A preliminary report
8. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
9. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
10. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients
11. Intratumoural heterogeneity of lp deletions and MYCN amplification in neuroblastomas
12. Allelic loss of chromosome 1p as a predictorof unfavorable outcome in patients with neuroblastoma
13. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: A Children's Cancer Group study
14. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: A Pediatric Oncology Group study
15. Neuroblastoma with focal MYCN amplification and bone marrow infiltration: A staging and treatment dilemma